By contrast, our data indicated that temporal VD3 treatment was enough to sustain prolonged IGFBP-3 expression, suggesting that a temporal higher concentration, rather than a constant concentration, of VD3 may be important in maximizing its efficacy in prostate cancer treatment. The gene discussed is IGFBP3; the disease is prostate carcinoma.